AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04379596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine: administered orally
Study NCT04379596 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab: administered as an IV infusion
Study NCT03520595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium 50mg twice daily
Description: CLP with ostectomy done in patients whose biologic width and crown height is insufficient
Study NCT03520595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills and distilled water 3 pills,3 times daily
Description: CLP with ostectomy done in patients whose biologic width and crown height is insufficient
Study NCT00519701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Study NCT02206217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiple-Segment spectacle lens
Description: A multifocal spectacle lens that corrects distance refraction and provides myopic defocus images simultaneously. The myopic defocus aims at slowing down myopia progression.
Study NCT04285632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometrics exercises
Description: Counter Movement Jump exercise. The subject will be placed in an upright standing position, with his hands on his hip. It will perform a rapid downward movement in which it will flex the hips and knees and, immediately, a rapid extension of the legs that will result in the maximum vertical jump. During the flight phase the subject will keep the legs straight. The landing will be done with both feet at the same time. The intervention will be carried out for 300 seconds, in 2 series of 30 jumps each and with 3 minutes of rest between series.~Drop Jump exercise. The players will be placed on a step, standing and with their feet shoulder-width apart. They will drop forward, landing with both feet at the same time. Upon touching the ground they will perform a maximum vertical jump. The intervention will be carried out for 600 seconds, in 2 series of 25 jumps each, and with 3 minutes of rest between series.
Study NCT04379596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: administered as an IV infusion
Study NCT05197946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Research unsedated MRI scans (outside of usual care) will be performed using a 3T Philips scanner at the F.M. Kirby Research Center. An MRI scanning protocol will be at the F.M. Kirby Research Center; the protocol will not last more than 1.5 hours. Acquisitions will include a triplanar survey, functional and anatomical multi-slice imaging of the brain as well as MRI of selected spinal levels. Protocols will be used that do not involve use of contrast agents and limit power/tissue absorption as well as otherwise remain within FDA and Kirby Center safety regulations. When possible, MRI will be performed within 3 months of initial survey/interview administration. If MRI is scheduled >3 months after initial survey/interview administration, a brief survey will be re-administered to screen for changes in pain/clinical status.
Study NCT03672110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: intervention: different advagraf dosing in the study compared to the control arm, see above
Study NCT03672110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf
Description: intervention: different advagraf dosing in the study compared to the control arm, see above
Study NCT03177603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586881
Description: GSK2586881 is a clear colorless liquid for IV infusion over 3- 5 minutes and will be administered a maximum dose of 0.8 mg/kg.
Study NCT05014906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic acid
Description: 45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
Study NCT05014906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelaic acid
Description: 45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
Study NCT04379596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin: administered as an IV infusion
Study NCT04379596 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab: administered as an IV infusion
Study NCT04379596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion
Study NCT00509236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 25 mg (one 25-mg tablet) once daily
Study NCT00509236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: 2.5 mg (1/2 of a 5-mg tablet) once daily, up to 10 mg twice daily (four 5-mg tablets), for a maximum of 20 mg
Study NCT04504201 — intervention group
Intervention type: OTHER
Intervention: Focus Group
Description: Breast cancer patients and oncology clinicians will participate in separate focus groups discussing patient-centered communication about healthy weight.
Study NCT02504125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision
Study NCT02504125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 100 mL of normal saline intravenously approximately 15 minutes before incision
Study NCT04379596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin: administered as an IV infusion
Study NCT04379596 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab: administered as an IV infusion
Study NCT04379596 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: Volrustomig: administered as an IV infusion
Study NCT01770210 — intervention group
Intervention type: DRUG
Intervention: Patients on atorvastatin treatment
Description: Statins Therapy
Study NCT01209637 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: exercise training min. 4 times a day for at least 30 min
Study NCT01209637 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive exercise training
Description: Intensive exercise training for 4 times / day incl. interval training at 95% individual threshold
Study NCT02493400 — intervention group
Intervention type: OTHER
Intervention: No intervention in the follow up study.
Study NCT04379596 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Rilvegostomig: administered as an IV infusion
Study NCT04265430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast Agent
Description: Given IV
Study NCT04265430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04265430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04265430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05120518 — intervention group
Intervention type: OTHER
Intervention: Collection of post mortem tissue donation
Description: Collection of post mortem tissue from pediatric participants with cancer and non-cancer tumor types from whom post mortem tissue donation and autopsy consent is obtained.
Study NCT04435756 — intervention group
Intervention type: OTHER
Intervention: Biomarker Analysis
Description: Correlative study
Study NCT04435756 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Product Collection
Description: Undergo collection of blood
Study NCT02793674 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fisher & Paykel high flow nasal cannula
Description: Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.
Study NCT02793674 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vapotherm high flow nasal cannula
Description: Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.
Study NCT00601172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant
Description: Experimental NK-1 receptor antagonist
Study NCT00601172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Standard antiemetics
Study NCT00601172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Standard antiemetics
Study NCT00601172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match IV casopitant
Study NCT00601172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: Standard antiemetics
Study NCT00601172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Standard antiemetics
Study NCT02498353 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: preoperative short-course radiotherapy with local boost
Description: Except the clinical target volume(CTV),a gross tumour volume（GTV）is delineated，and give a dose of PTV-GTV:30Gy/5F
Study NCT02498353 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: preoperative short-course radiotherapy without local boost
Description: Preoperative short-course radiotherapy without local boost,the dose of radiotherapy is PTV-CTV 25Gy/5F
Study NCT02498353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TME surgery
Description: both study group and control group received surgery under TME principle after radiotherapy
Study NCT02498353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME surgery
Description: both study group and control group received surgery under TME principle after radiotherapy
Study NCT04601558 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The letters with the Cochrane abstracts in the form of blog-shots
Description: The active intervention were letters with the remainder on participant's own cardiovascular risk factors, a participant's own count of 10-year risk of cardiovascular disease, and Cochrane abstract in the form of blog-shots and personal advice in reducing cardiovascular disease risk.~There were three Cochrane blog-shots. The first was about calcium in prevention of high blood pressure, the second was about the effect of reducing saturated fat acids in eating habits and the third consisted evidence of green and black tea for the prevention of cardiovascular diseases.~The letters were sent three times, every two months after the participants received first letter about cardiovascular disease risk.
Study NCT04601558 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: The letters with remainder on cardiovascular risk factors
Description: The passive intervention were letters with the remainder on participant's own cardiovascular risk factors and participant's own count of 10-year risk of cardiovascular disease.~The letters were sent three times, every two months after the participants received first letter about cardiovascular disease risk.
Study NCT03298282 — intervention group
Intervention type: OTHER
Intervention: OCT (Optical Coherence Tomography)
Description: Coronary images by OCT and selective CTA and FFR values will be registered.
Study NCT03298282 — intervention group
Intervention type: OTHER
Intervention: Coronary CTA
Description: Coronary images by OCT and Coronary CTA and FFR values will be registered.
Study NCT03298282 — intervention group
Intervention type: OTHER
Intervention: FFR
Description: Coronary images by OCT and selective CTA and FFR values will be registered.
Study NCT03306901 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Ivor Lewis esophagectomy or McKeown esophagectomy and systematic lymphadenectomy
Study NCT03306901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 3,200 \~ 4,000mg/m2 intravenously for 4 to 5 days.
Study NCT03306901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 45\~60mg intravenously over 1 hour on day 1
Study NCT03306901 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 45 Gy irradiation (5 days a week for 5 weeks)
Study NCT03777670 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Drop of blood for RNA and metabolic analysis
Study NCT04543136 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpeediCath® Standard male
Description: Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male.
Study NCT04543136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New intermittent Variant 1 catheter for males
Description: Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 catheter.
Study NCT04543136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New intermittent Variant 2 catheter for males
Description: Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 catheter.
Study NCT00494104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day
Description: Infants receive daily 0.5 ml of code labeled supplement
Study NCT00494104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day
Description: Infants receive daily 0.5 ml of code labeled supplement
Study NCT02470858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF+ASV
Description: Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed-dose combination (FDC) tablet; administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
Study NCT02470858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF+DCV+SMV
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Study NCT02470858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF+DCV+ASV
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
Study NCT01432496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 150 mg
Description: Nebulization of Ropivacaine 150 mg in the peritoneal cavity
Study NCT01432496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 15 ml
Description: Nebulization of saline 15 ml in the peritoneal cavity
Study NCT03367507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sub-symptom aerobic exercise
Description: Both groups will be instructed to perform their respective aerobic exercise program the following day after completing their first treadmill test. Participants will be instructed to exercise at their prescribed intensity for a maximum of 30 minutes a day, 4-5 days a week. They will be asked to postpone the exercise until the next day if they experience significant increases in symptoms from usual resting levels. Exercise type will be the participant's choice, however we will ask the participant refrain from contact/high risk activities including any modalities that might induce rapid and aggressive head movements.
Study NCT03367507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sub-symptom aerobic exercise
Description: Both groups will be instructed to perform their respective aerobic exercise program the following day after completing their first treadmill test. Participants will be instructed to exercise at their prescribed intensity for a maximum of 30 minutes a day, 4-5 days a week. They will be asked to postpone the exercise until the next day if they experience significant increases in symptoms from usual resting levels. Exercise type will be the participant's choice, however we will ask the participant refrain from contact/high risk activities including any modalities that might induce rapid and aggressive head movements.
Study NCT00186966 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome)
Description: See Detailed Description section for details of treatment interventions.
Study NCT00785317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angemin vs Activelle
Description: 1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP or 1 mg of oral E2 in continuous combination with 0.5 mg of NETA during six months.
Study NCT00785317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angemin vs Activelle
Description: 1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP or 1 mg of oral E2 in continuous combination with 0.5 mg of NETA during six months.
Study NCT03503825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [Tc-99m]-RPI-T-087 Injection
Description: A single intravenous injection of \[Tc-99m\]-RPI-T-087 followed by SPECT/CT imaging of the knee (all subjects) and whole body planar imaging (Healthy volunteers only)
Study NCT03975764 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of fecal sample
Description: Analysis of fecal microbiome
Study NCT00186966 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan
Description: See Detailed Description section for details of treatment interventions.
Study NCT00186966 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hematopoietic stem cell transplant
Description: See Detailed Description section for details of treatment interventions.
Study NCT01786486 — intervention group
Intervention type: DEVICE
Intervention: Amplatzer Cardiac Plug
Study NCT01639859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastography
Description: The elastography in vivo will be performed before the prostatectomy. The elastography ex vivo will be performed after radical prostatectomy.
Study NCT00511979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin
Study NCT00511979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere insulin
Study NCT00511979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular human insulin
Study NCT01802255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sedation with inhaled anesthetic via AnaConDa.
Study NCT01802255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Intravenous sedation.
Study NCT01319799 — intervention group
Intervention type: OTHER
Intervention: Open heart surgery
Description: TCD count of microembolic signals during surgical aortic valve replacement
Study NCT01247428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiStent SES
Description: The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
Study NCT01105286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues
Description: Once daily application
Study NCT02489110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Webnovela
Study NCT02489110 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information
Study NCT01683162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClinOleic
Description: the lipid of all-in-one, 0.5-3.5g/kg.d
Study NCT01683162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipofundin
Description: the lipid of all-in-one, 0.5-3.5g/kg.d
Study NCT01683162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Description: the lipid of all-in-one, 0.5-3.5g/kg.d
Study NCT04580563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OctaplasLG®
Description: Patient receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
Study NCT04580563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: Patient receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
Study NCT04903171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INCENTIVE VISITING A GARDEN : ENRICHED OR CONVENTIONAL SENSORY GARDEN
Description: Carers invites every the participants of group 2 and 3 visiting their respective gardens (enriched or conventional sensory garden)
Study NCT04903171 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: INCENTIVE VISITING A GARDEN : ENRICHED OR CONVENTIONAL SENSORY GARDEN
Description: Carers invites every the participants of group 2 and 3 visiting their respective gardens (enriched or conventional sensory garden)